Kinetic change of serum carcinoembryonic antigen can early predict progression in patients with metastatic non-small cell lung cancer during maintenance therapy with bevacizumab plus pemetrexed.

about

Kinetic change of serum carcinoembryonic antigen can early predict progression in patients with metastatic non-small cell lung cancer during maintenance therapy with bevacizumab plus pemetrexed.

Item

http://www.wikidata.org/entity/Q45907827

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Kinetic change of serum carcin ...... h bevacizumab plus pemetrexed.

@en

Kinetic change of serum carcin ...... h bevacizumab plus pemetrexed.

@nl

type

Item

label

Kinetic change of serum carcin ...... h bevacizumab plus pemetrexed.

@en

Kinetic change of serum carcin ...... h bevacizumab plus pemetrexed.

@nl

prefLabel

Kinetic change of serum carcin ...... h bevacizumab plus pemetrexed.

@en

Kinetic change of serum carcin ...... h bevacizumab plus pemetrexed.

@nl

P1476

Kinetic change of serum carcin ...... h bevacizumab plus pemetrexed.

@en

P2093

Fang Shi

http://www.w3.org/2001/XMLSchema#string

Haiyong Wang

http://www.w3.org/2001/XMLSchema#string

Hui Zhu

http://www.w3.org/2001/XMLSchema#string

Jinming Yu

http://www.w3.org/2001/XMLSchema#string

Li Kong

http://www.w3.org/2001/XMLSchema#string

Ming Yang

http://www.w3.org/2001/XMLSchema#string

Nasha Zhang

http://www.w3.org/2001/XMLSchema#string

Wang Jing

http://www.w3.org/2001/XMLSchema#string

P2860

Human carcinoembryonic antigen functions as a general inhibitor of anoikis

DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Cancer statistics, 2016

Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer: a prospective analysis

A double-blind, randomized phase II study of dicycloplatin plus paclitaxel versus carboplatin plus paclitaxel as first-line therapy for patients with advanced non-small-cell lung cancers

Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer

Measures of response: RECIST, WHO, and new alternatives.

Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

P304

74910-74916

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.20456

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29088833

http://www.w3.org/2001/XMLSchema#string

P921

bevacizumab

P932

5650388

http://www.w3.org/2001/XMLSchema#string